TY - JOUR
TI - The central biobank and virtual biobank of BIOMARKAPD: A resource for studies on neurodegenerative diseases
AU - Reijs, B.L.R.
AU - Teunissen, C.E.
AU - Goncharenko, N.
AU - Betsou, F.
AU - Blennow, K.
AU - Baldeiras, I.
AU - Brosseron, F.
AU - Cavedo, E.
AU - Fladby, T.
AU - Froelich, L.
AU - Gabryelewicz, T.
AU - Gurvit, H.
AU - Kapaki, E.
AU - Koson, P.
AU - Kulic, L.
AU - Lehmann, S.
AU - Lewczuk, P.
AU - Lleó, A.
AU - Maetzler, W.
AU - De Mendonça, A.
AU - Miller, A.-M.
AU - Molinuevo, J.L.
AU - Mollenhauer, B.
AU - Parnetti, L.
AU - Rot, U.
AU - Schneider, A.
AU - Simonsen, A.H.
AU - Tagliavini, F.
AU - Tsolaki, M.
AU - Verbeek, M.M.
AU - Verhey, F.R.J.
AU - Zboch, M.
AU - Winblad, B.
AU - Scheltens, P.
AU - Zetterberg, H.
AU - Visser, P.J.
JO - Frontiers in Neurology
PY - 2015
VL - 6
TODO - OCT
SP - null
PB - Frontiers Media S.A
SN - null
TODO - 10.3389/fneur.2015.00216
TODO - biological marker, Alzheimer disease;  Article;  assay;  biobank;  blood sampling;  body fluid;  cerebrospinal fluid;  cognition;  degenerative disease;  diagnostic procedure;  diffuse Lewy body disease;  frontotemporal dementia;  health care facility;  mild cognitive impairment;  multiinfarct dementia;  Parkinson disease;  plasma;  prognostic assessment;  progressive supranuclear palsy;  Shy Drager syndrome;  standardization;  validation process
TODO - Biobanks are important resources for biomarker discovery and assay development. Biomarkers for Alzheimer's and Parkinson's disease (BIOMARKAPD) is a European multicenter study, funded by the EU Joint Programme-Neurodegenerative Disease Research, which aims to improve the clinical use of body fluid markers for the diagnosis and prognosis of Alzheimer's disease (AD) and Parkinson's disease (PD). The objective was to standardize the assessment of existing assays and to validate novel fluid biomarkers for AD and PD. To support the validation of novel biomarkers and assays, a central and a virtual biobank for body fluids and associated data from subjects with neurodegenerative diseases have been established. In the central biobank, cerebrospinal fluid (CSF) and blood samples were collected according to the BIOMARKAPD standardized pre-analytical procedures and stored at Integrated BioBank of Luxembourg. The virtual biobank provides an overview of available CSF, plasma, serum, and DNA samples at each site. Currently, at the central biobank of BIOMARKAPD samples are available from over 400 subjects with normal cognition, mild cognitive impairment (MCI), AD, frontotemporal dementia (FTD), vascular dementia, multiple system atrophy, progressive supranuclear palsy, PD, PD with dementia, and dementia with Lewy bodies. The virtual biobank contains information on over 8,600 subjects with varying diagnoses from 21 local biobanks. A website has been launched to enable sample requests from the central biobank and virtual biobank. © 2015 Reijs, Teunissen, Goncharenko, Betsou, Blennow, Baldeiras, Brosseron, Cavedo, Fladby, Froelich, Gabryelewicz, Gurvit, Kapaki, Koson, Kulic, Lehmann, Lewczuk, Lleó, Maetzler, de Mendonça, Miller, Molinuevo, Mollenhauer, Parnetti, Rot, Schneider, Simonsen, Tagliavini, Tsolaki, Verbeek, Verhey, Zboch, Winblad, Scheltens, Zetterberg and Visser.
ER -